[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336063-105":59,"doc-detail-336063-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","histone-modification-linked-prognostic-model-for-ovarian-cancer-reveals-lbx2-as-a-novel-growth-promoter","Histone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter","","Ovarian cancer is a deadly disease with limited treatment options and poor overall survival. This study evaluates histone modification-related genes as prognostic predictors using transcriptome data from multiple cohorts, including bulk RNA-Seq and single-cell scRNA-Seq. Gene set enrichment highlights histone modification pathway involvement, while Lasso-derived differentially expressed genes yield a five-gene TCGA-OV risk model. The risk score correlates with T-cell and M1 macrophage immune infiltration, shows more frequent mutations in the high-risk group, screens candidate drugs, and in vitro confirms model gene expression patterns.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/histone-modification-linked-prognostic-model-for-ovarian-cancer-reveals-lbx2-as-a-novel-growth-promoter/336063/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/histone-modification-linked-prognostic-model-for-ovarian-cancer-reveals-lbx2-as-a-novel-growth-promoter/336063.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the goal of this study for ovarian cancer patients?","Question",{"text":113,"@type":114},"To investigate how histone modification-related genes can predict ovarian cancer prognosis and support improved therapeutic decision-making.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the prognostic model constructed in the study?",{"text":118,"@type":114},"Differentially expressed genes between histone modification-high and -low groups were identified, and a prognostic model was built using five selected prognostic genes from the TCGA-OV cohort.",{"name":120,"@type":111,"acceptedAnswer":121},"What biological and clinical associations were found with the risk score model?",{"text":122,"@type":114},"The risk score related to immune infiltration of T cells and M1 macrophages, with more prevalent mutations in the high-risk group than the low-risk group.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336063,1790164543,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","DOI: 10. 1111/jcmm.18260  \nOR I G I NAL ART I C L E  \nHistone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter  \nJian Xiong1  | Hongyuan Liang2 | Xiang Sun1 | Kefei Gao1  \n1Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China 2Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China  \nCorrespondence  \nJian Xiong, Xiang Sun and Kefei  \nGao, Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. Email: [2022760187@gzhmu.edu.cn](2022760187@gzhmu.edu.cn), [sunxiang624@gwcmc.org](sunxiang624@gwcmc.org) and gaokefei_[fezx@yeah. net](fezx@yeah. net)  \nFunding information  \nPlan on enhancing scientific research in GMU, Grant/Award Number: 02-410- 2302169XM; Science and Technology Program of Guangzhou, China, Grant/ Award Number: 2023A03J0881, 2023A04J1244, 2024A03J0807 and 2024A03J0956; Research foundation of Guangzhou Women and Children's Medical Center for Clinical Doctor, Grant/Award Number: 2020RC003 and 2021BS044  \nAbstract  \nOvarian cancer (OC) is a deadly disease with limited treatment options and poor overall survival rates. This study aimed to investigate the role of histone modificationrelated genes in predicting the prognosis of OC patients. Transcriptome data from multiple cohorts, including bulk RNA-Seq data and single-cell scRNA-Seq data, were collected. Gene set enrichment analysis was used to identify enriched gene sets in the histone modification pathway. Differentially expressed genes (DEGs) between histone modification-high and histone modification-low groups were identified using Lasso regression. A prognostic model was constructed using five selected prognostic genes from the DEGs in the TCGA-OV cohort. The study found enrichment of gene sets in the histone modification pathway and identified five prognostic genes associated with OC prognosis. The constructed risk score model based on histone modificationrelated genes was correlated with immune infiltration of T cells and M1 macrophages. Mutations are more prevalent in the high-risk group compared to the low-risk group. Several drugs were screened against the model genes. Through in vitro experiments, we confirmed the expression patterns of the model genes. LBX2 facilitates the proliferation of OC. Histone modification-related genes have the potential to serve as biomarkers for predicting OC prognosis. Targeting these genes may lead to the development of more effective therapies for OC. Additionally, LBX2 represents a novel cell proliferation promoter in OC carcinogenesis.  \nK E Y WO R D S  \nimmune infiltration, LBX2, ovarian cancer, prognosis, proliferation  \n1 | INTRODUCTION  \nOvarian cancer (OC) is a significant health concern, with a high mortality rate and limited treatment options.1 Currently, various strategies have been developed for the prevention and treatment of OC. For individuals at high-risk, such as those with a family history  \nof OC or carriers of BRCA1/BRCA2 gene mutations, prophylactic oophorectomy is recommended. Early-stage patients may undergo comprehensive staging surgery, while late-stage patients may undergo cytoreductive surgery. Following surgery, patients typically receive combination chemotherapy based on platinum agents, such as cisplatin/carboplatin plus paclitaxel, cisplatin/carboplatin plus  \n\n| Jian Xiong and Hongyuan Liang have contributed equally to this work. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2024 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. |\n\nJ Cell Mol Med. 2024;28:e18260 .  \n[https://doi.org/10.1111/jcmm.1826","cbCaiqEKYxY9MPiO","https://ap.wps.com/l/cbCaiqEKYxY9MPiO","pdf",16075261,17,"English","# Abstract\n# Introduction\n## Clinical background and treatment landscape\n## Rationale for histone modification and biomarker search","[{\"question\":\"What was the goal of this study for ovarian cancer patients?\",\"answer\":\"To investigate how histone modification-related genes can predict ovarian cancer prognosis and support improved therapeutic decision-making.\"},{\"question\":\"How was the prognostic model constructed in the study?\",\"answer\":\"Differentially expressed genes between histone modification-high and -low groups were identified, and a prognostic model was built using five selected prognostic genes from the TCGA-OV cohort.\"},{\"question\":\"What biological and clinical associations were found with the risk score model?\",\"answer\":\"The risk score related to immune infiltration of T cells and M1 macrophages, with more prevalent mutations in the high-risk group than the low-risk group.\"}]","Histone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter | PDF",1790013441,43]